menu
    • menu

    Company profile for Valo Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    VALO TX is a developer of novel cancer immunotherapies that are projected to transform the lives of millions of cancer patients. Our unique approach to immunotherapy in cancer, based on an oncolytic virus non-covalently combined with tumor-specific peptides, delivers a highly immunogenic and rapidly adaptable tumor vaccination platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Valo Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    62 Harpes Road, Oxford, UK. OX2 7QL
    Telephone
    Telephone
    +44 20 3920 7649‬
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.valotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/valo-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ValoTherapeuti1

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ValoTx Appoints Marcella Origgi as CEO
    ValoTx Appoints Marcella Origgi as CEO

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058128/0/en/ValoTx-Appoints-Marcella-Origgi-from-Johnson-Johnson-Innovation-as-CEO.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share
    Valo Secures €19M Funding, Expands Clinical Trials
    Valo Secures €19M Funding, Expands Clinical Trials

    10 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/10/3039464/0/en/Valo-Therapeutics-announces-EUR-19m-of-investment-funding-and-expanded-clinical-trials.html

    GLOBENEWSWIRE
    10 Mar 2025
    Share Share
    Lisata & Valo Announce Preclinical Research Collaboration
    Lisata & Valo Announce Preclinical Research Collaboration

    06 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/06/2975782/18623/en/Lisata-Therapeutics-and-Valo-Therapeutics-Announce-Preclinical-Research-Collaboration.html

    GLOBENEWSWIRE
    06 Nov 2024
    Share Share
    Valo Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial
    Valo Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial

    29 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/29/2787495/0/en/Valo-Therapeutics-Announces-Regulatory-Approval-to-Expand-Phase-I-Immuno-oncology-Trial-into-Sarcoma.html

    GLOBENEWSWIRE
    29 Nov 2023
    Share Share
    Valo Announces Acquisition of Bruker's Latest Mass Spectrometer Platform
    Valo Announces Acquisition of Bruker's Latest Mass Spectrometer Platform

    10 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/10/2757151/0/en/Valo-Therapeutics-Announces-Acquisition-of-Bruker-Corporation-s-Latest-Mass-Spectrometer-Platform-for-Tumor-Antigen-Identification-with-ValoTx-s-PeptiCHIP-Technology.html

    GLOBENEWSWIRE
    10 Oct 2023
    Share Share
    ValoTx, Texcell ink collaboration to evaluate immune responses to PeptiCRAd-1
    ValoTx, Texcell ink collaboration to evaluate immune responses to PeptiCRAd-1

    15 Jun 2023

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=159719&sid=2

    PHARMABIZ
    15 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search